Journal
ONCOLOGY
Volume 100, Issue 6, Pages 320-330Publisher
KARGER
DOI: 10.1159/000523850
Keywords
Hepatocellular carcinoma; Atezolizumab plus bevacizumab; Malignant potential; Poorly differentiated; Rapid progressive disease; F-18-fluorodeoxyglucose positron emission tomography/computed tomography
Categories
Funding
- Okinaka Memorial Institute for Medical Research
- Japanese Ministry of Health, Labour and Welfare
Ask authors/readers for more resources
The utility of F-18-fluorodeoxyglucose positron emission tomography/computed tomography (F-18-FDG-PET/CT) as a predictor of early progressive disease (e-PD) in hepatocellular carcinoma (HCC) patients treated with atezolizumab plus bevacizumab (Atezo/Bev) was investigated in this study. The results showed that a tumor-to-normal liver ratio (TLR) >= 2, indicating higher oncological aggressiveness, was associated with lower objective response rates, higher e-PD rates, and worse early progression-free survival (e-PFS). Pretreatment F-18-FDG-PET/CT may be a useful new predictor of e-PD and may enable early decision-making based on early treatment changes following Atezo/Bev treatment of HCC.
Background and Aims: The aim of this study was to identify the utility of F-18-fluorodeoxyglucose positron emission tomography/computed tomography (F-18-FDG-PET/CT) as a predictor of early progressive disease (e-PD) in patients with hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab (Atezo/Bev). Methods: Twenty consecutive patients with measurable intrahepatic target nodules who received Atezo/Bev treatment were reviewed. The oncological aggressiveness of tumors estimated by F-18-FDG-PET/CT was analyzed using the rate of e-PD within 12 weeks and early progression-free survival (e-PFS) and overall survival (OS). Multivariate analysis was used to identify potential confounders for PD during Atezo/Bev therapy. Results: Using the Response Evaluation Criteria in Solid Tumors version 1.1, a tumor-to-normal liver ratio (TLR) >= 2, indicating higher oncological aggressiveness in HCCs, was associated with lower objective response rates compared with TLR values <2 (18% vs. 33%, respectively). Moreover, TLR values >= 2 were significantly associated with higher e-PD rates compared with TLR values <2 (64% vs. 11%, respectively) and worse e-PFS (p = 0.021). In multivariate analysis, TLR >= 2 showed marginal significance as a predictor of e-PD (p = 0.053), and utility as a predictor for worse e-PFS (hazard ratio, 7.153; 95% confidence interval, 1.258-40.689; p = 0.027). In contrast, no significant differences in OS with/without e-PD were observed during the treatment course. In this study, 8 patients experienced e-PD and almost 40% of patients experienced acceptable disease control following subsequent lenvatinib treatment. Conclusion: Pretreatment F-18-FDG-PET/CT may be a useful new predictor of e-PD and may enable early decision-making based on early treatment changes following Atezo/Bev treatment of HCC. (C) 2022 The Author(s). Published by S. Karger AG, Basel
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available